H5N1 News and Research

Latest H5N1 News and Research

Scientists create GM chicken that does not spread bird flu to other chickens

"Scientists have developed genetically modified [GM] chickens that don't transmit bird flu [H5N1] to other chickens," HealthDay News/Bloomberg Businessweek reports.

18 Jan 2011

Chicks that don’t pass on bird flu

Influenza from birds, commonly known as H5N1 avian flu, has killed at least 306 people during the past seven years and innumerable birds and poultry. Now a team of scientists in Britain have developed a way to breed poultry that are genetically resistant to H5N1 or any other avian flu virus. The study by Scientists from Cambridge and Edinburgh universities was reported in the Jan. 13 issue of Science.

13 Jan 2011

Antibodies produced by people who recovered from H1N1 offer clues for universal flu vaccine

The antibodies produced by individuals who fought off H1N1 (swine flu) infection last year may bring researchers one step closer to their quest to develop a "universal" flu vaccine, U.S. researchers said Monday, HealthDay News/Bloomberg Businessweek reports.

12 Jan 2011

Potential single vaccine for permanent immunity to all influenza

The search for a universal flu vaccine has received a boost from a surprising source: the 2009 H1N1 pandemic flu strain.

10 Jan 2011

CEL-SCI initiates Multikine Phase III trail for head and neck cancer

CEL-SCI Corporation announced today that it has commenced its Phase III clinical trial for Multikine®, the Company's flagship immunotherapy. CEL-SCI has now completed all of the manufacturing and regulatory requirements to begin enrollment of the study.

29 Dec 2010

Sinovac's inactivated EV71 vaccine clinical trial against HFMD receives Chinese SFDA approval

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that it received approval from the China State Food and Drug Administration (SFDA) to commence clinical trials for its proprietary inactivated EV71 vaccine against Hand, Foot and Mouth Disease (HFMD).

28 Dec 2010

Medicago completes first part of H5N1 vaccine Phase II trial

Medicago, a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced that the last dose of vaccine has been administered completing the first part of the Company's Phase II human clinical trial with its H5N1 Avian Influenza vaccine.

23 Dec 2010

Seaside purchases additional $2.5M of NanoViricides' Series B Convertible Preferred Stock

NanoViricides, Inc., announced today that it had consummated a closing with Seaside 88, LP ("Seaside"), a Florida limited partnership, on Seaside's purchase of an additional $2.5M of the Company's Series B Convertible Preferred Stock. Seaside has financed several leading-edge bio-pharma companies, including Cytori Therapeutics, Inc., Generex Biotechnology Corporation, and NovaDel Pharma, Inc. among others.

22 Dec 2010

Exosomes derived from lymphoma, colorectal cancer patients circulated through Aethlon's Hemopurifier

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has demonstrated the ability to capture immunosuppressive exosomes derived from individuals with lymphoma and colorectal cancer.

20 Dec 2010

CEL-SCI receives Ukraine government approval for Multikine Phase III clinical trial in head and neck cancer

CEL-SCI Corporation announced today it has received governmental approval from the Health Authority, Ministry of Health of Ukraine, to begin enrollment of subjects for a Phase III clinical trial of Multikine® in Ukraine. Multikine is the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. Ukraine is one of nine countries to participate in this global Phase III trial. The Phase III trial will be run at about 48 clinical centers, of which about 6 centers will be in Ukraine.

16 Dec 2010

Intercell to stop further development of Travelers' Diarrhea Vaccine Patch

Intercell AG announced today preliminary clinical results on its investigational Travelers' Diarrhea (TD) Vaccine Patch program and the decision not to pursue further the development of this vaccine candidate. The decision was made following the receipt of results of its randomized and placebo-controlled Phase III study (ELT301) with 2036 travelers from Europe to Mexico and Guatemala as well as the pilot efficacy Phase II trial (ELT209) with 723 travelers from Europe to India.

13 Dec 2010

CEL-SCI reports net income of $10.48M for fiscal 2010 vs. $40.9M loss for fiscal 2009

CEL-SCI Corporation reported financial results today for the fiscal year ended September 30, 2010.

13 Dec 2010

Vical's Vaxfectin adjuvant boosts immune response of DNA-based vaccines against cancer

Vical Incorporated announced today that the company's Vaxfectin® adjuvant has significantly boosted the immune response of DNA-based vaccines against a range of pathogens and cancer in preclinical models from rodents to non-human primates. Vaxfectin® has demonstrated similar effects with protein- and peptide-based vaccines in preclinical models.

13 Dec 2010

SEEK reports Phase I safety trail for investigational flu vaccine

SEEK, a leading UK privately-owned drug-discovery group, today presented data on the successful conclusion of a Phase I safety and tolerability study for its investigational Universal Influenza Vaccine, FLU-v, at the World Influenza Congress in Amsterdam (7-9 December).

8 Dec 2010

Fraunhofer USA CMB receives FDA approval to initiate Phase I clinical trial of H5N1 influenza vaccine

Fraunhofer USA Center for Molecular Biotechnology announced today it has received approval from the Food and Drug Administration to proceed with the first human clinical trial of plant-produced H5N1 influenza vaccine.

6 Dec 2010

Baxter licenses Vero cell-based influenza vaccine technology to Takeda

Baxter International Inc. and Takeda Pharmaceutical Company Limited today announced that the parties have completed a Development, License and Technology Transfer Agreement. Under the terms of the agreement, Takeda and Baxter will expand upon their previously announced collaboration to bring Vero cell culture-based influenza vaccines to the Japanese market.

From Baxter International Inc. 2 Dec 2010

New book investigates past influenza pandemics

Influenza pandemics have been among the most unpredictable and devastating natural disasters, but discussions about them are usually confined to specialists. This book makes fascinating reading for anyone who wants to understand the context of pandemics but may have been deterred by the technical detail.

1 Dec 2010

QIAGEN to supply point-of-need molecular veterinary diagnostics for disease detection in emerging countries

QIAGEN has been selected to contribute to the fight against infectious diseases in animals in emerging countries by supplying an international pilot project associated with the United Nations with portable devices to perform ultra-fast molecular testing in the field.

From QIAGEN Manchester Limited 29 Nov 2010

Medicago, Genopole expand collaboration

Medicago Inc., a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced an extension to its partnering agreement of July 2009 with Genopole®. Medicago and Genopole® will also work towards the creation a laboratory for research on vaccine and antibody targets of interest for France in terms of public health and biodefense.

26 Nov 2010

CEL-SCI holds clinical investigator meeting for Multikine Phase III clinical trial in head, neck cancer

CEL-SCI Corporation today announced that the Company held a clinical investigator meeting during the week of November 14th for its Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer.

23 Nov 2010

H5N1 News and Research

Latest H5N1 News and Research

Scientists create GM chicken that does not spread bird flu to other chickens

Chicks that don’t pass on bird flu

Antibodies produced by people who recovered from H1N1 offer clues for universal flu vaccine

Potential single vaccine for permanent immunity to all influenza

CEL-SCI initiates Multikine Phase III trail for head and neck cancer

Sinovac's inactivated EV71 vaccine clinical trial against HFMD receives Chinese SFDA approval

Medicago completes first part of H5N1 vaccine Phase II trial

Seaside purchases additional $2.5M of NanoViricides' Series B Convertible Preferred Stock

Exosomes derived from lymphoma, colorectal cancer patients circulated through Aethlon's Hemopurifier

CEL-SCI receives Ukraine government approval for Multikine Phase III clinical trial in head and neck cancer

Intercell to stop further development of Travelers' Diarrhea Vaccine Patch

CEL-SCI reports net income of $10.48M for fiscal 2010 vs. $40.9M loss for fiscal 2009

Vical's Vaxfectin adjuvant boosts immune response of DNA-based vaccines against cancer

SEEK reports Phase I safety trail for investigational flu vaccine

Fraunhofer USA CMB receives FDA approval to initiate Phase I clinical trial of H5N1 influenza vaccine

Baxter licenses Vero cell-based influenza vaccine technology to Takeda

New book investigates past influenza pandemics

QIAGEN to supply point-of-need molecular veterinary diagnostics for disease detection in emerging countries

Medicago, Genopole expand collaboration

CEL-SCI holds clinical investigator meeting for Multikine Phase III clinical trial in head, neck cancer

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

H5N1 News and Research

Latest H5N1 News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in